Share this video  

EHA 2022 | Alliance A061202: POM-DEX vs IXA-POM-DEX in R/R multiple myeloma

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, reports the findings of Alliance A061202 (NCT02004275), a Phase I/II study comparing the safety and efficacy of pomalidomide, dexamethasone and ixazomib (IXA-POM-DEX) versus pomalidomide and dexamethasone (POM-DEX) in lenalidomide-refractory patients with multiple myeloma. Dr Richardson first outlines the study design and explains that patients treated with the IXA-POM-DEX triplet had a significantly higher progression-free survival (PFS). In addition, Dr Richardson explains that this all-oral combination was well-tolerated and there was no COVID-19-related mortality. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter